Novartis


Novartis   link
Lieu: Bâle
Hauptporte - MainGate, Fabrikstrasse 2, 4056 Basel

Domaine: Pharmacologie
Lié:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

logo

Pharmacologie - Santé - 23.09
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (I T) formulation in older patients with SMA to further support registration - Basel, September 23, 2020 - Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA).
Santé - Pharmacologie - 21.09

Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score - confirming substantial benefit for premenopausal women with HR+/HER2- advanced breast cancer (aBC), based on significant overall survival (OS) benefit and improved quality of life, in the MONALEESA-7 study 1 -   Kisqali is also th

Pharmacologie - Santé - 19.09

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone 1 -   14+ months OS improvement was achieved in patients with lung or liver metastases, which are obs

Pharmacologie - Santé - 16.09

COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1 -   Adjuvant treatment with standard-of-care targeted therapy Tafinlar + Mekinist reduced the risk of relapse or death by 49% compared to placebo 1 -   Updated data show Tafi

Pharmacologie - Santé - 14.09

In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1 -   In a key secondary endpoint, more than half of Beovu patients were maintained on a three-month dosing interval through year one, following the loa

Pharmacologie - Santé - 11.09

Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent 1 -   Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse

Pharmacologie - Santé - 19.09

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma 1-4 -   Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the CO

Santé - Économie - 16.09

First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access Targets to increase patients reached in lowand middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagshi

Pharmacologie - Santé - 14.09

Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD   -   The update includes the additional characterization of retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation 1 -   Novartis has established a multidisciplinary panel o

Pharmacologie - Santé - 11.09

New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide 1 Additional safety data in over 1,800 patients who continued Kesimpta treatment or s

Pharmacologie - Santé - 8.09

Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta (ofatumumab) -the first and only self-administered, targeted B-cell therapy for relapsing forms of MS (RMS )- Mayzent (siponimod) and Gilenya (fingolimod) -   New pivotal data from ASCLEPIOS trials evaluating the efficacy and sa